
Contents

List of Contributors, vii

Preface, x

Part 1: Learning from a Worldwide Perspective

- 1 Are patterns and prevalence changing?, 3
Hashem B. El-Serag
- 2 Why is the tumour different in Africa?, 11
Nimzing G. Ladej
- 3 Control by vaccination: Asian and Taiwan experience, 18
Jia-Horng Kao
- 4 The view from the United Kingdom, 24
Shahid A. Khan, Mireille B. Toledano, Abigail Zabron, Mehtan Ahmed, and Simon D. Taylor-Robinson
- 5 The view from the United States, 29
Hitoshi Maruyama and Arun J. Sanyal
- 6 New challenges of the NAFLD and HIV epidemics, 35
Quentin M. Anstee and Janice Main

Part 2: Influence of Tumour Characteristics

- 7 Controversies in pathology, 45
Tania Roskams
- 8 Not to forget the unusual tumour, 53
Bernard C. Portmann
- 9 What can be learned from molecular diagnostic techniques and genetic signatures?, 60
Tariq Moatter and Saeed Hamid

Part 3: Complexities of Patient Assessment and Scoring Systems

- 10 Looking after the liver as well as the tumour, 67
Roger Williams
- 11 Comparative performances of staging systems for hepatocellular cancer: early HCC considerations, 75
Peter D. Peng and Timothy M. Pawlik
- 12 Rival scoring systems: do they offer more?, 81
Angelo Sangiovanni and Massimo Colombo
- 13 Is it possible to detect early lesions effectively?, 91
Ryota Masuzaki and Masao Omata
- 14 What is the value of country-based surveillance programmes?, 97
Peter Ott

Part 4: Choice of Radiological Diagnostic Technique

- 15 Computed tomography or magnetic resonance imaging for the diagnosis of hepatocellular carcinoma, 107
Wladyslaw Gedroyc
- 16 Is Microbubble ultrasound useful?, 114
Adrian Lim
- 17 Value of PET scanning, 118
Tara D. Barwick, Imene Zerizer, and Adil Al-Nahhas

Part 5: Can Treatment be Tailored to the Patient?

- 18 Who could benefit from chemoembolisation?, 127
Gisèle N’Kontchou, Olivier Seror, and Michel Beaugrand

- 19** Are drug-eluting beads worth using?, 136
Christopher N. Hacking and Pradesh Kumar
- 20** What is the future of image-guided radiofrequency ablation for hepatocellular carcinoma?, 142
Riccardo Lencioni
- 21** Alternative ablation techniques for hepatocellular carcinoma, 149
John Karani
- 22** Justification for sorafenib and chemotherapy, 154
Philip J. Johnson
- 23** When to consider surgery?, 160
Emmanuel Melloul, Mickaël Lesurtel, and Pierre-Alain Clavien
- 24** Transplant considerations, 168
Myron Schwartz

Part 6: What Does the Future Hold?

- 25** Dipstick markers for diagnosis: feasible or not?, 179
Mohamed I.F. Shariff and Simon D. Taylor-Robinson
- 26** Targeted gene therapy for hepatocellular carcinoma: a reality?, 184
Christopher Binny, Marco Della Peruta, and Amit C. Nathwani
- 27** Is immune modulation a possibility?, 191
Tim F. Greten and Firouzeh Korangy
- 28** Systemic therapy for hepatocellular carcinoma: future directions, 199
Daniel H. Palmer, Matthew E. Cramp

Index, 212

Colour plate section can be found facing page 86